Twitter | Search | |
Search Refresh
Puneeth Iyengar Jan 10
Excited to announce we have enrolled our 100th pt on NRG LU-002. Thanks to all the investigators and patients! Lets keep in going in 2020!
Reply Retweet Like
Wally Curran Jan 11
⁩ describing progress on ⁦⁩ LU005, a novel phase III trial for patients with limited stage small cell lung cancer ⁩ ⁦⁩ ⁦
Reply Retweet Like
Mylin Torres Jan 11
NRG BR005 - Trimodality imaging did not predict pCR in 105 pts when using non-pCR definition inclusive of DCIS. Better correlation seen in Her2+ patients, clip retrieval, 6 or more bx cores ⁦
Reply Retweet Like
Thomas B. Julian, MD Jan 10
A lasting tribute for Dr. Fisher ⁦ provided by Dr. Wolmark.
Reply Retweet Like
NRG Oncology 7h
Don't forget the next meeting is coming up in July and being held in Washington, DC. Save the Date!
Reply Retweet Like
Tim Kruser Jan 10
The head of Dr. Norman Wolmark movingly eulogizes the father of our clinical trials framework Bernie Fisher by reminding a full room that he: A) didn’t tolerate mediocrity & B) didn’t suffer fools Words to live by.
Reply Retweet Like
Wally Curran Jan 11
⁦Dr Stephen Lin speaking on ⁦⁩ trial ARCHON 1 ay Lung Cancer Committee. Very novel concept! ⁦⁩ ⁦
Reply Retweet Like
Benjamin Kann, MD Jan 9
Looking forward to discussing , cancer imaging, and moving from box to bedside at the Digital Health session bright and early tomorrow AM. Come for the deep learning, stay for the baby Yoda memes.
Reply Retweet Like
Jon Kiddy Jan 11
1-on-1 session is underway!
Reply Retweet Like
Mylin Torres Jan 11
Finished accruing at last! Great job everybody ⁦
Reply Retweet Like
Thomas B. Julian, MD Jan 11
Dr. Julia White provides an update on RT and local regional trials ⁦
Reply Retweet Like
Thomas B. Julian, MD Jan 11
Dr. Wolmark leading the NRG Breast Cancer Workshop. Always a crowd pleaser!
Reply Retweet Like
Eric Donnelly Jan 9
Excellent overview of the data on PARPi in ovarian cancer by Joyce Liu, can see how much has been done to find further ways to benefit our patients
Reply Retweet Like
Andrea Hagemann, MD, MSCI Jan 11
Moving from bench to bedside isn’t easy, but is working tirelessly to bring an exciting new drug to our patients. Love the discussion on in at
Reply Retweet Like
Matt Spraker Jan 10
Some good tips for enhancing trial accrual from Dr. Dewdney at
Reply Retweet Like
Sophia Kamran, MD Jan 10
Inspiring talk! Exciting science in IO...key is to really understand what drives resistance to immunotherapy and how to INTELLIGENTLY prime tumors, not develop a hundred new IO therapies...👀👀
Reply Retweet Like
Jame Abraham Jan 11
Thanks to Nancy Soto and Mitch Machtay for strong partnership and leadership: Research Strategy ⁦⁩ ⁦
Reply Retweet Like
Pamela Samson, MD Jan 11
presenting the schema, bio correlates, and globally enrolling centers for PACIFIC-4 at evaluating the role of adjuvant durvalumab after SBRT for early stage NSCLC to ⬆️ PFS. So impt to eval if we can translate excellent local control to systemic control!
Reply Retweet Like
Jame Abraham Jan 11
Final session of ⁦⁩ The Research Strategy Meeting !
Reply Retweet Like
Ross Harrison Jan 9
What’s next for PARP inhibitors? Moving away from combinations with chemotherapy and towards combinations that address/overcome mechanisms of PARP resistance.
Reply Retweet Like